Chikungunya News and Research

RSS

NIH awards $18 million to develop novel chikungunya vaccine

The Access to Advanced Health Institute (AAHI) announced today that it has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.

3 Aug 2023

Novel molecules inspired by the immune system inactivate several viruses

Antiviral therapies are notoriously difficult to develop, as viruses can quickly mutate to become resistant to drugs. But what if a new generation of antivirals ignores the fast-mutating proteins on the surface of viruses and instead disrupts their protective layers?

2 Aug 2023

Peptoid antiviral therapy inactivates three viruses in lab tests

Just as bacteria can develop antibiotic resistance, viruses can also evade drug treatments. Developing therapies against these microbes is difficult because viruses often mutate or hide themselves within cells.

2 Aug 2023

Climate change-driven extreme weather events impacting HIV control in Asia Pacific

Climate change-driven extreme weather events, sea level rise, changes in temperature, and air and water pollution are impacting control of HIV in the Asia Pacific region, a science gathering heard.

28 Jul 2023

CEPI and HMRI partner to accelerate development of pandemic vaccines

CEPI, the Coalition for Epidemic Preparedness Innovations, and the Houston Methodist Research Institute (HMRI), have today announced a partnership to combine cutting-edge artificial intelligence (AI) technology with established laboratory techniques to speed up development of future vaccines against novel viral threats (also known as Disease X).

18 Jul 2023

Dengue outbreak overlapped COVID-19 crisis in Key Largo, Florida in 2020: Call for enhanced disease testing protocols

Detection and response to a dengue outbreak in Florida during the COVID-19 pandemic in 2020, highlighting the challenges of diagnosing febrile illnesses and the need for surveillance. This study examines the impact and management of dengue cases in the context of the ongoing pandemic.

5 Jul 2023

New CRISPR-based system could eliminate malaria-carrying mosquitoes

Malaria remains one of the world's deadliest diseases. Each year malaria infections result in hundreds of thousands of deaths, with the majority of fatalities occurring in children under five.

5 Jul 2023

Study identifies the predictors of post-coronavirus disease 2019 (COVID-19) syndrome symptoms

Study identifies the predictors of post-coronavirus disease 2019 (COVID-19) syndrome symptoms.

30 Jun 2023

Understanding the biological effects of SARS-CoV-2 persistence in children

Researchers analyzed the most recent knowledge about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Jun 2023

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Albumedix Ltd., a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.

From Albumedix Ltd. 29 Jun 2023

Europe's battle against Aedes mosquitoes: growing threat of mosquito-borne diseases

Study described how cases of all types of mosquito-borne diseases are increasing in Europe.

26 Jun 2023

Plant based compound peruvoside may be able to prevent up to 12 medically important viruses

Peruvoside, a plant-based compound that is commonly used to treat heart failure, has been discovered to be able to prevent up to 12 medically important viruses, all originating from different virus families.

22 Jun 2023

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Researchers performed a double-blinded, phase III randomized trial.

15 Jun 2023

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.

12 Jun 2023

Scientists identify broad-spectrum antiviral agents that can target multiple RNA virus families

A new study has identified potential broad-spectrum antiviral agents that can target multiple families of RNA viruses that continue to pose a significant threat for future pandemics.

28 Apr 2023

Did a military lab spill anthrax into public waterways? New book reveals details of a US leak

Unsterilized laboratory wastewater from the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland, spewed out the top of a rusty 50,000-gallon outdoor holding tank, the pressure catapulting it over the short concrete wall that was supposed to contain hazardous spills.

25 Apr 2023

Chikungunya News and Research

NIH awards $18 million to develop novel chikungunya vaccine

Novel molecules inspired by the immune system inactivate several viruses

Peptoid antiviral therapy inactivates three viruses in lab tests

Climate change-driven extreme weather events impacting HIV control in Asia Pacific

CEPI and HMRI partner to accelerate development of pandemic vaccines

Dengue outbreak overlapped COVID-19 crisis in Key Largo, Florida in 2020: Call for enhanced disease testing protocols

New CRISPR-based system could eliminate malaria-carrying mosquitoes

Study identifies the predictors of post-coronavirus disease 2019 (COVID-19) syndrome symptoms

Understanding the biological effects of SARS-CoV-2 persistence in children

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Europe's battle against Aedes mosquitoes: growing threat of mosquito-borne diseases

Plant based compound peruvoside may be able to prevent up to 12 medically important viruses

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

Scientists identify broad-spectrum antiviral agents that can target multiple RNA virus families

Did a military lab spill anthrax into public waterways? New book reveals details of a US leak

Cellulose nanocrystals as a barrier against mosquito bites

New research set to benefit people suffering from debilitating joint pain after tropical viral infection

Thousands of unique arboviruses and flaviviruses identified from samples collected between 1954-2018

World Health Day: Giving Universal Health Coverage a Platform

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News